[
    [
        {
            "time": "2018-03-15",
            "original_text": "The Kiplinger Dividend 15 Is On a Roll",
            "features": {
                "keywords": [
                    "Kiplinger Dividend",
                    "roll"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "The Kiplinger Dividend 15 Is On a Roll",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "Don’t Abandon Gilead Stock After Weak Q4 Results",
            "features": {
                "keywords": [
                    "Gilead",
                    "weak Q4",
                    "abandon"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Don’t Abandon Gilead Stock After Weak Q4 Results",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-03-05",
            "original_text": "Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs",
            "features": {
                "keywords": [
                    "FDA",
                    "J&J",
                    "antidepressant",
                    "CHMP",
                    "drugs"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-02-19",
            "original_text": "Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC",
            "features": {
                "keywords": [
                    "Roche",
                    "Tecentriq",
                    "EC",
                    "NSCLC"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]